MSD’s Keytruda/Lenvima Combination Leads Promotions in the European Ovarian, Endometrial, and Pan-Tumor dMMR Cancer Market in Q4

AbbVie positioned Elahere as “the first ADC FRα-positive, platinum-resistant ovarian cancer.” It highlighted the MIRASOL study results and the improved PFS and OS versus chemotherapy.

GlaxoSmithKline promoted Zejula’s PRIMA study and real-world data in ovarian cancer, featuring sustained PFS benefit across biomarker groups for individualized decision-making.

MSD announced that Keytruda/Lenvima was approved as an option for endometrial cancer after platinum therapy regardless of biomarker status, with KEYNOTE-775 demonstrating significant benefits across dMMR and pMMR populations. A new campaign was introduced.

Pharma& announced Rubraca’s approval for ovarian cancer as first-line maintenance regardless of BRCA status based on the ATHENA trial PFS benefit.